Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9;27(12):e970-e972.
doi: 10.1093/oncolo/oyac181.

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens

Matthew C Hiemenz  1 , Ryon P Graf  1 , Kelsie Schiavone  1 , Lukas Harries  1 , Geoffrey R Oxnard  1 , Jeffrey S Ross  1   2 , Richard S P Huang  1
Affiliations

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens

Matthew C Hiemenz et al. Oncologist. .

Abstract

Challenges with sequencing tissue samples from patients with prostate cancer have been reported in clinical trials. To assess the success rate of comprehensive genomic profiling (CGP) for prostate cancer patients, we analyzed a real-world cohort who underwent sequencing of their prostate tissue sample as well as a subset of patients with a reflex liquid biopsy. Overall, a significant majority (82%) of tissue prostate carcinoma samples yielded reportable CGP results. Of those samples that were unsuccessful, most (75%) were inadequate samples that did not meet pre-established criteria to advance into sequencing. For cases where liquid CGP was performed if tissue CGP was unsuccessful, mutations that were likely attributable to prostate carcinoma were observed in most cases and all cases were successful in generating a report. These results suggest that, for CGP testing, prostate cancer tissue is a reasonable matrix type and that liquid samples can be effectively used as an alternative to tissue.

Keywords: precision medicine; prostate cancer; real-world.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Real world prostate carcinoma testing success rate by processing step and assay.
See this image and copyright information in PMC

References

    1. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer v4.2022. Published 2022. Accessed November 24, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
    1. Gonzalez D, Mateo J, Stenzinger A, et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J Pathol Clin Res. 2021;7(4):311-325. 10.1002/cjp2.203 - DOI - PMC - PubMed
    1. Hussain M, Corcoran C, Sibilla C, et al. Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib). Clin Cancer Res. 2022;28(8):1518-1530. 10.1158/1078-0432.CCR-21-3940 - DOI - PubMed
    1. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-1031. 10.1038/nbt.2696 - DOI - PMC - PubMed
    1. Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One. 2020;15(9):e0237802. 10.1371/journal.pone.0237802 - DOI - PMC - PubMed